RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
China Resources Pharmaceutical Group Stock

China Resources Pharmaceutical Group Revenue 2024

China Resources Pharmaceutical Group Revenue

288.34 B CNY

Ticker

3320.HK

ISIN

HK0000311099

WKN

A2ATTU

In 2024, China Resources Pharmaceutical Group's sales reached 288.34 B CNY, a 17.83% difference from the 244.7 B CNY sales recorded in the previous year.

The China Resources Pharmaceutical Group Revenue history

YEARREVENUE (undefined CNY)GROSS MARGIN (%)
2028e391.399,80
2027e372.1410,30
2026e34910,98
2025e318.7312,03
2024e288.3413,30
2023244.715,67
2022218.1815,41
2021215.5414,94
2020200.4216,11
2019204.4516,64
2018189.6918,41
2017172.5316,39
2016156.7115,39
2015146.5715,83
2014135.7515,83
2013116.9517,23

China Resources Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into China Resources Pharmaceutical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by China Resources Pharmaceutical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects China Resources Pharmaceutical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of China Resources Pharmaceutical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into China Resources Pharmaceutical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing China Resources Pharmaceutical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on China Resources Pharmaceutical Group’s growth potential.

China Resources Pharmaceutical Group Revenue, EBIT and net profit per share

DateChina Resources Pharmaceutical Group RevenueChina Resources Pharmaceutical Group EBITChina Resources Pharmaceutical Group Net Income
2028e391.39 B undefined18.4 B undefined4.77 B undefined
2027e372.14 B undefined18.04 B undefined4.91 B undefined
2026e349 B undefined16.48 B undefined5.62 B undefined
2025e318.73 B undefined15.17 B undefined5.25 B undefined
2024e288.34 B undefined13.69 B undefined4.66 B undefined
2023244.7 B undefined12.11 B undefined3.85 B undefined
2022218.18 B undefined9.95 B undefined3.5 B undefined
2021215.54 B undefined9.3 B undefined3.43 B undefined
2020200.42 B undefined9.93 B undefined3.3 B undefined
2019204.45 B undefined9.85 B undefined3.29 B undefined
2018189.69 B undefined11.9 B undefined3.98 B undefined
2017172.53 B undefined10.53 B undefined3.48 B undefined
2016156.71 B undefined9.48 B undefined2.82 B undefined
2015146.57 B undefined8.83 B undefined2.85 B undefined
2014135.75 B undefined8.43 B undefined2.65 B undefined
2013116.95 B undefined8.3 B undefined2.64 B undefined

China Resources Pharmaceutical Group stock margins

The China Resources Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of China Resources Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for China Resources Pharmaceutical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the China Resources Pharmaceutical Group's sales revenue. A higher gross margin percentage indicates that the China Resources Pharmaceutical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the China Resources Pharmaceutical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the China Resources Pharmaceutical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the China Resources Pharmaceutical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the China Resources Pharmaceutical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the China Resources Pharmaceutical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

China Resources Pharmaceutical Group Margin History

China Resources Pharmaceutical Group Gross marginChina Resources Pharmaceutical Group Profit marginChina Resources Pharmaceutical Group EBIT marginChina Resources Pharmaceutical Group Profit margin
2028e15.67 %4.7 %1.22 %
2027e15.67 %4.85 %1.32 %
2026e15.67 %4.72 %1.61 %
2025e15.67 %4.76 %1.65 %
2024e15.67 %4.75 %1.62 %
202315.67 %4.95 %1.58 %
202215.41 %4.56 %1.6 %
202114.94 %4.32 %1.59 %
202016.11 %4.96 %1.65 %
201916.64 %4.82 %1.61 %
201818.41 %6.27 %2.1 %
201716.39 %6.1 %2.02 %
201615.39 %6.05 %1.8 %
201515.83 %6.02 %1.94 %
201415.83 %6.21 %1.95 %
201317.23 %7.1 %2.26 %

China Resources Pharmaceutical Group Aktienanalyse

What does China Resources Pharmaceutical Group do?

China Resources Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding China Resources Pharmaceutical Group's Sales Figures

The sales figures of China Resources Pharmaceutical Group originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing China Resources Pharmaceutical Group’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize China Resources Pharmaceutical Group's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in China Resources Pharmaceutical Group’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about China Resources Pharmaceutical Group stock

How much revenue did China Resources Pharmaceutical Group generate this year?

China Resources Pharmaceutical Group has achieved a revenue of 288.34 B CNY this year.

How much was the turnover of the company China Resources Pharmaceutical Group compared to the previous year?

The revenue of China Resources Pharmaceutical Group has increased by 17.83% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of China Resources Pharmaceutical Group?

The revenue of China Resources Pharmaceutical Group is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of China Resources Pharmaceutical Group measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of China Resources Pharmaceutical Group so important for investors?

The revenue of China Resources Pharmaceutical Group is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does China Resources Pharmaceutical Group pay?

Over the past 12 months, China Resources Pharmaceutical Group paid a dividend of 0.16 CNY . This corresponds to a dividend yield of about 3.63 %. For the coming 12 months, China Resources Pharmaceutical Group is expected to pay a dividend of 0.17 CNY.

What is the dividend yield of China Resources Pharmaceutical Group?

The current dividend yield of China Resources Pharmaceutical Group is 3.63 %.

When does China Resources Pharmaceutical Group pay dividends?

China Resources Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, October, October.

How secure is the dividend of China Resources Pharmaceutical Group?

China Resources Pharmaceutical Group paid dividends every year for the past 12 years.

What is the dividend of China Resources Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.17 CNY are expected. This corresponds to a dividend yield of 3.84 %.

In which sector is China Resources Pharmaceutical Group located?

China Resources Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von China Resources Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of China Resources Pharmaceutical Group from 10/30/2024 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did China Resources Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 10/30/2024.

What was the dividend of China Resources Pharmaceutical Group in the year 2023?

In the year 2023, China Resources Pharmaceutical Group distributed 0.15 CNY as dividends.

In which currency does China Resources Pharmaceutical Group pay out the dividend?

The dividends of China Resources Pharmaceutical Group are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von China Resources Pharmaceutical Group

Our stock analysis for China Resources Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of China Resources Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.